N/A
N=260
Tranexamic Acid in Off-pump Coronary Surgery
Off Pump Coronary Artery Bypass Surgery
Bottom Line
View on ClinicalTrials.gov: NCT01064167 ↗Enrolled (actual)
260
Serious AEs
0.0%
Results posted
Feb 2011
Primary outcome: Primary: Number of Patients Required Allogenic Red Blood Cells Transfusion — 37; 54 participants — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Tranexamic Acid (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Primary completion
- Oct 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Required Allogenic Red Blood Cells Transfusion |
37; 54 | <0.05 sig |
| SECONDARY Postoperative Chest Tube Drainage |
654; 891 | <0.05 sig |
Summary
The aim of this prospective, randomized, double-blinded, placebo-controlled study was to evaluate the effects of tranexamic acid, a synthetic antifibrinolytic drug, on the postoperative bleeding and transfusion requirements in patients undergoing off-pump coronary artery bypass graphing (OPCAB) surgery.
Eligibility Criteria
Inclusion Criteria
- Patients for elective offpump coronary artery bypass surgery
Exclusion Criteria
- A history of bleeding disorders
- Active chronic hepatitis or cirrhosis
- Chronic renal insufficiency (serum creatinine > 2 mg/dL)
- Preoperative anemia (Hb < 10 g/dL)
- Previous cardiac surgery
- Myocardial infarction < 7 days before surgery
Data sourced from ClinicalTrials.gov (NCT01064167). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.